{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T13:51:59Z","timestamp":1781531519714,"version":"3.54.5"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T00:00:00Z","timestamp":1568160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genet"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pompe disease is a lysosomal storage disorder caused by the deficiency of acid alpha-glucosidase (EC. 3.2.1.20) due to mutations in human<jats:italic>GAA<\/jats:italic>gene. The objective of the present study was to examine clinical and molecular characteristics of infantile-onset Pompe disease (IOPD) in Thailand.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twelve patients with infantile-onset Pompe disease (IOPD) including 10 Thai and two other Asian ethnicities were enrolled. To examine the molecular characteristics of Pompe patients,<jats:italic>GAA<\/jats:italic>gene was analyzed by PCR amplification and direct Sanger-sequencing of 20 exons coding region. The novel mutations were transiently transfected in COS-7 cells for functional verification. The severity of the mutation was rated by study of the GAA enzyme activity detected in transfected cells and culture media, as well as the quantity and quality of the proper sized GAA protein demonstrated by western blot analysis. The GAA three dimensional structures were visualized by PyMol software tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All patients had hypertrophic cardiomyopathy, generalized muscle weakness, and undetectable or\u2009&lt;\u20091% of GAA normal activity. Three patients received enzyme replacement therapy with variable outcome depending on the age of the start of enzyme replacement therapy (ERT). Seventeen pathogenic mutations including four novel variants: c.876C\u2009&gt;\u2009G (p.Tyr292X), c.1226insG (p.Asp409GlyfsX95), c.1538G\u2009&gt;\u2009A (p.Asp513Gly), c.1895\u2009T\u2009&gt;\u2009G (p.Leu632Arg), and a previously reported rare allele of unknown significance: c.781G\u2009&gt;\u2009A (p.Ala261Thr) were identified. The rating system ranked p.Tyr292X, p. Asp513Gly and p. Leu632Arg as class \u201cB\u201d and p. Ala261Thr as class \u201cD\u201d or \u201cE\u201d. These novel mutations were located in the N-terminal beta-sheet domain and the catalytic domain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The present study provides useful information on the mutations of<jats:italic>GAA<\/jats:italic>gene in the underrepresented population of Asia which are more diverse than previously described and showing the hotspots in exons 14 and 5, accounting for 62% of mutant alleles. Almost all mutations identified are in class A\/B. These data can benefit rapid molecular diagnosis of IOPD and severity rating of the mutations can serve as a partial substitute for cross reactive immunological material (CRIM) study.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12881-019-0878-8","type":"journal-article","created":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T06:53:33Z","timestamp":1568184813000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical course, mutations and its functional characteristics of infantile-onset Pompe disease in Thailand"],"prefix":"10.1186","volume":"20","author":[{"given":"Lukana","family":"Ngiwsara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-2176","authenticated-orcid":false,"given":"Duangrurdee","family":"Wattanasirichaigoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thipwimol","family":"Tim-Aroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitiwan","family":"Rojnueangnit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saisuda","family":"Noojaroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthaporn","family":"Khongkraparn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phannee","family":"Sawangareetrakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Ketudat-Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratana","family":"Charoenwattanasatien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voraratt","family":"Champattanachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chulaluck","family":"Kuptanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suthipong","family":"Pangkanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisnuson","family":"Svasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,11]]},"reference":[{"issue":"5","key":"878_CR1","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"Priya S Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267\u201388.","journal-title":"Genetics in Medicine"},{"issue":"2","key":"878_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HM van den Hout","year":"2003","unstructured":"van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332\u201340.","journal-title":"Pediatrics"},{"key":"878_CR3","unstructured":"Leslie N, Bailey L. Pompe disease. GeneReviews\u00ae [Internet]. M.P. Adam, H.H. Ardinger, R.A. Pagon, et al., editors.Seattle (WA), University of Washington, Seattle,1993-2018. Initial Posting: August 31, 2007, Last Update: May 11, 2017."},{"key":"878_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11910-011-0236-5","volume":"12","author":"C Angelini","year":"2011","unstructured":"Angelini C, Semplicini C. Enzyme replacement therapy for Pompe disease. Curr Neurol Neurosci Rep. 2011;12:70\u20135.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"878_CR5","first-page":"3389","volume-title":"The Metabolicand Molecular Bases of Inherited Disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R. Glycogen storage disease type II: acid alpha-glucosidase (acid maltose) deficiency. In: Scriver CR, editor. The Metabolicand Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill; 2001. p. 3389\u2013420.","edition":"8"},{"issue":"2","key":"878_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1042\/bj2720493","volume":"272","author":"LH Hoefsloot","year":"1990","unstructured":"Hoefsloot LH, Hoogeveen-Westerveld M, Reuser AJ, Oostra BA. Characterization of the human lysosomal alpha-glucosidase gene. Biochem J. 1990;272(2):493\u20137.","journal-title":"Biochem J"},{"issue":"4","key":"878_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1089\/dna.1991.10.283","volume":"10","author":"F Martiniuk","year":"1991","unstructured":"Martiniuk F, Bodkin M, Tzall S, Hirschhorn R. Isolation and partial characterization of the structural gene for human acid alpha glucosidase. DNA Cell Biol. 1991;10(4):283\u201392.","journal-title":"DNA Cell Biol"},{"issue":"8","key":"878_CR8","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.1074\/jbc.M404008200","volume":"280","author":"RJ Moreland","year":"2005","unstructured":"Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, et al. Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem. 2005;280(8):6780\u201391.","journal-title":"J Biol Chem"},{"issue":"3","key":"878_CR9","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","volume":"268","author":"HA Wisselaar","year":"1993","unstructured":"Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ. Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem. 1993;268(3):2223\u201331.","journal-title":"J Biol Chem"},{"key":"878_CR10","unstructured":"The Pompe Disease Mutation Database ( http:\/\/www.pompecenter.nl update on May 2016). Accessed 1 Oct 2018."},{"key":"878_CR11","doi-asserted-by":"publisher","first-page":"E13","DOI":"10.1002\/humu.20745","volume":"29","author":"M Kroos","year":"2008","unstructured":"Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, et al. GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat. 2008;29:E13\u201326.","journal-title":"Hum Mutat"},{"key":"878_CR12","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/humu.22108","volume":"33","author":"M Kroos","year":"2012","unstructured":"Kroos M, Hoogeveen-Westerveld M, Michelakakis H, Pomponio R, Van der Ploeg A, Halley D, et al. GAA Database Consortium. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Hum Mutat. 2012;33:1161\u20135.","journal-title":"Hum Mutat"},{"key":"878_CR13","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1042\/bj2890687","volume":"289","author":"MM Hermans","year":"1993","unstructured":"Hermans MM, de Graaff E, Kroos MA, Wisselaar HA, Willemsen R, Oostra BA, et al. The conservative substitution Asp-645>Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J. 1993;289:687\u201393.","journal-title":"Biochem J"},{"issue":"21","key":"878_CR14","doi-asserted-by":"crossref","first-page":"13507","DOI":"10.1016\/S0021-9258(18)92727-4","volume":"266","author":"MM Hermans","year":"1991","unstructured":"Hermans MM, Kroos MA, van Beeumen J, Oostra BA, Reuser AJ. Human lysosomal alpha-glucosidase. Characterization of the catalytic site. J Biol Chem. 1991;266(21):13507\u201312.","journal-title":"J Biol Chem"},{"issue":"1","key":"878_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1006\/bbrc.1995.2139","volume":"213","author":"CY Lin","year":"1995","unstructured":"Lin CY, Shieh JJ. Identification of a de Novo point mutation resulting in infantile form of Pompe's disease. Biochem Biophys Res Commun. 1995;213(1):367.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"878_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.nmd.2006.09.004","volume":"17","author":"RE Palmer","year":"2007","unstructured":"Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoles NA. Pompe disease (glycogen storage disease type II) in Argentineans: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord. 2007;17(1):16\u201322.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"878_CR17","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1006\/bbrc.1998.8255","volume":"244","author":"ML Huie","year":"1998","unstructured":"Huie ML, Tsujino S, Sklower Brooks S, Engel A, Elias E, Bonthron DT, et al. Glycogen storage disease type II: identification of four novel missense mutations (D645N, G648S, R672W, R672Q) and two insertions\/deletions in the acid alpha-glucosidase locus of patients of differing phenotype. Biochem Biophys Res Commun. 1998;244(3):921\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"878_CR18","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00415-008-0714-0","volume":"255","author":"L Wan","year":"2008","unstructured":"Wan L, Lee CC, Hsu CM, Hwu WL, Yang CC, Tsai CH, et al. Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II. J Neurol. 2008;255(6):831\u20138.","journal-title":"J Neurol"},{"issue":"1","key":"878_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ajmg.c.31319","volume":"160c","author":"DS Bali","year":"2012","unstructured":"Bali DS, Goldstein JL, Banugaria S, Dai J, Mackey J, Rehder C, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C: Semin Med Genet. 2012;160c(1):40\u20139.","journal-title":"Am J Med Genet C: Semin Med Genet"},{"issue":"4","key":"878_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/ejhg.2010.188","volume":"19","author":"S Zampieri","year":"2011","unstructured":"Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis MG, Bembi B, et al. Splicing mutations in glycogen-storage disease type II: evaluation of the full spectrum of mutations and their relation to patients' phenotypes. Eur J Hum Genet. 2011;19(4):422\u201331.","journal-title":"Eur J Hum Genet"},{"key":"878_CR21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1006\/bbrc.1994.2360","volume":"203","author":"M van der Kraan","year":"1994","unstructured":"van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, et al. Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun. 1994;203:1535\u201341.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"878_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S","volume":"11","author":"JJ Shieh","year":"1998","unstructured":"Shieh JJ, Lin CY. Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat. 1998;11(4):306\u201312.","journal-title":"Hum Mutat"},{"issue":"1","key":"878_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/humu.10286","volume":"23","author":"MM Hermans","year":"2004","unstructured":"Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23(1):47\u201356.","journal-title":"Hum Mutat"},{"issue":"10","key":"878_CR24","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/humu.20374","volume":"27","author":"AL Montalvo","year":"2006","unstructured":"Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27(10):999\u20131006.","journal-title":"Hum Mutat"},{"issue":"3","key":"878_CR25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/ahg.12236","volume":"82","author":"L Ngiwsara","year":"2018","unstructured":"Ngiwsara L, Ketudat-Cairns JR, Sawangareetrakul P, Charoenwattanasatien R, Champattanachai V, Kuptanon C, et al. p.X654R IDUA variant among Thai individuals with intermediate mucopolysaccharidosis type I and its residual activity as demonstrated in COS-7 cells. Ann Hum Genet. 2018;82(3):150\u20137.","journal-title":"Ann Hum Genet"},{"issue":"1","key":"878_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ymgme.2005.10.016","volume":"88","author":"T Okumiya","year":"2006","unstructured":"Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, et al. A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab. 2006;88(1):22\u20138.","journal-title":"Mol Genet Metab"},{"key":"878_CR27","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/bioinformatics\/btm091","volume":"23","author":"T Koressaar","year":"2007","unstructured":"Koressaar T, Remm M. Enhancements and modifications of primer design program Primer3. Bioinformatics. 2007;23:1289\u201391.","journal-title":"Bioinformatics."},{"key":"878_CR28","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/s41467-017-01263-3","volume":"8","author":"V Roig-Zamboni","year":"2017","unstructured":"Roig-Zamboni V, Cobucci-Ponzano B, Iacono R, Ferrara MC, Germany S, Bourne Y, et al. Structure of human lysosomal acid \u03b1-glucosidase-a guide for the treatment of Pompe disease. Nat Commun. 2017;8:1111.","journal-title":"Nat Commun"},{"issue":"8","key":"878_CR29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/ejhg.2008.34","volume":"16","author":"MA Kroos","year":"2008","unstructured":"Kroos MA, Mullaart RA, Van Vliet L, Pomponio RJ, Amartino H, Kolodny EH, et al. p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? Eur J Hum Genet. 2008;16(8):875\u20139.","journal-title":"Eur J Hum Genet"},{"key":"878_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jpeds.2015.10.078","volume":"169","author":"CF Yang","year":"2016","unstructured":"Yang CF, Yang CC, Liao HC, Huang LY, Chiang CC, Ho HC, et al. Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes. J Pediatr. 2016;169:174\u201380.","journal-title":"J Pediatr"},{"key":"878_CR31","doi-asserted-by":"publisher","first-page":"E1116","DOI":"10.1542\/peds.2008-3667","volume":"124","author":"YH Chien","year":"2009","unstructured":"Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124:E1116\u201325.","journal-title":"Pediatrics."},{"key":"878_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1089\/gtmb.2010.0038","volume":"14","author":"P Amarinthnukrowh","year":"2010","unstructured":"Amarinthnukrowh P, Tongkobpetch S, Kongpatanayothin A, Suphapeetiporn K, Shotelersuk V. p.D645E of acid \u03b1-glucosidase is the most common mutation in thai patients with infantile-onset pompe disease. Genet Test Mol Biomarkers. 2010;14:835\u20137.","journal-title":"Genet Test Mol Biomarkers"},{"key":"878_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymgmr.2017.10.009","volume":"14","author":"Y Fukuhara","year":"2017","unstructured":"Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, et al. A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Rep. 2017;14:3\u20139.","journal-title":"Mol Genet Metab Rep"},{"key":"878_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/hmg\/3.7.1081","volume":"3","author":"ML Huie","year":"1994","unstructured":"Huie ML, Chen AS, Brooks SS, Grix A, Hirschhorn R. A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). Hum Mol Genet. 1994;3:1081\u20137.","journal-title":"Hum Mol Genet"},{"key":"878_CR35","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0960-8966(01)00247-4","volume":"12","author":"R Fernandez-Hojas","year":"2002","unstructured":"Fernandez-Hojas R, Huie ML, Navarro C, Dominguez C, Roig M, Lopez-Coronas D, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromuscul Disord. 2002;12:159\u201366 Erratum in: Neuromuscul Disord 13 (2003) 427.","journal-title":"Neuromuscul Disord"}],"container-title":["BMC Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-019-0878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12881-019-0878-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12881-019-0878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:53:18Z","timestamp":1611103998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenet.biomedcentral.com\/articles\/10.1186\/s12881-019-0878-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1186\/s12881-019-0878-8","relation":{},"ISSN":["1471-2350"],"issn-type":[{"value":"1471-2350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,11]]},"assertion":[{"value":"30 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consents were obtained from all participants and the parents of the minor participants, following the Ramathibodi Hospital Institutional Review Board (protocol ID 06\u201355-46).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish was obtained from the parents or legal guardians of the participants whose individual data was detailed in the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"156"}}